Programme Steering Committee, Advisors and Topic Leaders
Introducing the DIA Europe 2018 Programme Steering Committee
REGULATORY SCIENCE CO-CHAIRS:
Luca Pani
Professor, Department of Psychiatry and Behavioral Sciences, University Of Miami School Of Medicine; Executive Director of Global Medical Innovation NeuroCog, USA
Michelle Rohrer
Global Head of PD Regulatory and Policy
F. Hoffmann-La Roche and Genentech, Switzerland
VALUE & ACCESS CO-CHAIRS:
Jens Grueger
Head of Global Pricing & Market Access
F. Hoffmann-La Roche, Switzerland
A.R. (Ad) Schuurman
Head of International Department
National Health Care Institute (ZIN), Netherlands
TRANSLATIONAL MEDICINE & SCIENCE CHAIR:
Salah-Dine Chibout
Global Head of Discovery & Investigative Safety (DIS)
Novartis Institutes, Switzerland
プログラム委員会
-
Salah-Dine Chibout
•
Global Head Discovery & Investigative Safety/Preclinical Safety Therapeutic Area
Novartis Pharma AG, Switzerland -
Jens Grueger, PhD
•
Director and Partner, Market Access and Pricing
Boston Consulting Group , Switzerland -
Luca Pani, MD
•
Former, AIFA; Professor, Department of Psychiatry and Behavioral Sciences
University of Miami, United States -
Michelle Rohrer, PhD
•
Senior Vice President, Global Head of Product Development Regulatory and Policy
Genentech, A Member of the Roche Group, United States -
Vivianne Arencibia
•
Independent Consultant
Arencibia Quality and Compliance Associates, United States -
Sabine Atzor, MPharm, RPh
•
Head of EU Regulatory Policies
F. Hoffmann-La Roche Ltd, Switzerland -
Ursula Busse, PhD, MBA
•
Head of Regulatory Affairs
Tigen Pharma SA, Switzerland -
João Duarte, MPharm, MSc
•
Vice President, Global Regulatory Affairs Excellence
Ipsen, France -
Sabine Haubenreisser, PhD, MSc
•
Principal Scientific Administrator, Stakeholders and Communication Division
European Medicines Agency, Netherlands -
Cordula Landgraf, RPh
•
Head of Networking
Swissmedic, Switzerland -
Francesco Pignatti, MD
•
Scientific Adviser for Oncology
European Medicines Agency, Netherlands -
Bettina Ryll
•
Member of the First EU Cancer Mission Board
MPNE, Vision Zero Cancer, Sweden -
Claudine Sapède, PharmD
•
Director, Global HTA Policy
NOVARTIS INTERNATIONAL, Switzerland -
Ad Schuurman, MBA, MSc
•
Head of the Business Contact Centre & International Affairs
National Health Care Institute (ZIN), Netherlands -
Indranil Bagchi, PhD, MSc
•
Global Head, Pricing & Market Access
GSK, United States -
Isabelle de Zegher, DrMed, MD, MS, MSc
•
Founder
b!loba, Belgium -
Petra Doerr, PharmD, RPh
•
Director
European Directorate for the Quality of Medicines and Healthcare (EDQM), France -
Vicki Edwards, RPh
•
Vice President, Pharmacovigilance Excellence and International QPPV
Abbvie, United Kingdom -
Georgy Genov, MD
•
Head of PHV Office, ad-interim Head of Quality & Safety of Medicines Department
European Medicines Agency, Netherlands -
Tony Humphreys, MPharm
•
Head of the Regulatory Science and Innovation Task Force
European Medicines Agency, Netherlands -
Merete Joergensen, MBA, MSc
•
Clinical Disclosure and Transparency Expert
Merete-J Consulting, Denmark -
Jordi Llinares Garcia, MS
•
Head of Research and Innovation
European Medicines Agency, Netherlands -
Manfred Maeder, PhD
•
Head of Device Development & Commercialization
Novartis, Switzerland -
Thomas Metcalfe, MBA
•
Personalised Healthcare Ecosystems
F. Hoffmann-La Roche, Switzerland -
Sharon Olmstead
•
Global Head, Regulatory & Development Policy
Novartis Pharmaceuticals Corporation, United States - Representative Invited • Merck KGaA, Germany
-
Thomas Senderovitz, DrMed, MD
•
Senior Vice President, Data Science
NovoNordisk, Denmark - Representative Invited • European Medicines Agency, Netherlands